STML News and Press, Stemline Therapeutics Inc. From 08/08/19

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public of...

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced that it intends to offer and sell, subje...

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) g...

"Arguing with anonymous strangers on the Internet is a sucker's game because they almost always turn out to be-or to be indistinguishable from-self-righteous sixteen-year-olds possessing infinite amounts of free time ." - Neal Stephenson, Cryptonomicon Investor sentiment and the overall m...

Stemline Therapeutics, Inc. (STML) Q2 2019 Earnings Conference Call August 02, 2019, 08:00 ET Company Participants Kenneth Hoberman - COO & Corporate Secretary Ivan Bergstein - Founder, President, CEO & Chairman Robert Francomano - SVP & Global Head, Commercial Davi...

Stemline Therapeutics ( STML ) Q2 results : Elzonris sales: $13M. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Stemline Therapeutics (NASDAQ: STML ): Q2 GAAP EPS of -$0.42 beats by $0.14 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Net revenue for ELZONRIS® was $13.0 million for the second quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on...

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on F...

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting, highlights recent clinical and regu...